12 Cheap Value Stocks to Buy Now According to Warren Buffett

Page 5 of 10

6. DaVita Inc. (NYSE:DVA

Forward Price-to-Earnings: 13.59

Berkshire Hathaway Stake Value: $5,375,745,012         

Number of Hedge Fund Holders: 43

With a low price-to-earnings multiple and a significant presence in Warren Buffett’s investment portfolio, DaVita Inc. (NYSE:DVA) earns a spot on our list of the 12 Cheap Value Stocks to Buy Now According to Warren Buffett.

DaVita Inc. (NYSE:DVA) reported strong Q1 2025 results on May 12, 2025. The company beat earnings estimates with an EPS of $2.00 (versus $1.75 expected), driven by strong results in patient care costs, phosphate binders, and the international segment. The severe flu season impacted the company’s treatment volume. Yet, it maintained a solid performance, allowing it to announce $680 million in share repurchases.

Despite a strong Q1 performance, Truist, on May 19, 2025, reduced its price target on DaVita Inc. (NYSE:DVA) from $170 to $164. Citing a mixed short-term outlook, the investment firm noted slower organic volume trends and secular pressures. Accordingly, Truist reduced its 2025 EPS estimate from $4.78 to $4.74, while maintaining the 2026 estimate in line with consensus. The analyst remains positive about the company’s dialysis business and long-term integrated care potential.

Ahead of upcoming Q2 earnings release, Zacks, on July 22, 2025, projected a 4.25% YoY increase in DaVita Inc. (NYSE:DVA)’s EPS, raising it to $2.70. Additionally, the investment research firm expects a 3.50% increase in DVA’s revenue, which would translate to $13.48 billion in revenue. Meanwhile, Zacks projects earnings and revenue to grow 11.16% and 5.15%, respectively, in 2025. The analyst keeps a ‘Hold’ rating on DVA.

Operating across the U.S. and the rest of the world, DaVita Inc. (NYSE:DVA) offers kidney dialysis and related services. It is included in our list of cheap value stocks to buy.

Page 5 of 10